Fanouriakis, Antonis <br/><br/>
Low disease activity-irrespective of serologic status at baseline-associated with reduction of corticosteroid dose and number of flares in patients with systemic lupus erythematosus treated with belimumab: A real-life observational study.  [electronic resource] 

 -  Seminars in arthritis and rheumatism  12 2018 
 - 467-474 p.  digital 
<br/><br/> Publication Type: Journal Article; Multicenter Study; Observational Study 
<br/><br/><label>ISSN: </label>1532-866X 
<br/><br/><label>Standard No.: </label>10.1016/j.semarthrit.2018.02.014  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adrenal Cortex Hormones--therapeutic use<br/>Adult<br/>Antibodies, Monoclonal, Humanized--therapeutic use<br/>Drug Therapy, Combination<br/>Female<br/>Humans<br/>Immunosuppressive Agents--therapeutic use<br/>Lupus Erythematosus, Systemic--blood<br/>Male<br/>Middle Aged<br/>Prednisone--therapeutic use<br/>Prospective Studies<br/>Severity of Illness Index<br/>Treatment Outcome